Prevalence and predictors of no lifetime utilization of mental health treatment among people with mental disorders in France: findings from the ‘Mental Health in General Population’ (MHGP) survey

  • Hélène Font
  • Jean-Luc Roelandt
  • Hélène Behal
  • Pierre-Alexis Geoffroy
  • Baptiste Pignon
  • Ali Amad
  • Nicolas Simioni
  • Guillaume Vaiva
  • Pierre Thomas
  • Alain Duhamel
  • Imane Benradia
  • Benjamin Rolland
Original Paper

Abstract

Purpose

No lifetime utilization of mental health treatment (NUMT) is an indicator of the treatment gap among people in need of treatment. Until now, the overall prevalence and predictors of NUMT have never been explored in France.

Methods

In a 39,617-respondent survey, participants were assessed for NUMT, i.e., no lifetime psychotherapy, psychopharmacotherapy, or psychiatric hospitalization. Mental disorders were investigated using the Mini International Neuropsychiatric Interview (MINI 5.0.0). MINI diagnoses were grouped into five categories: mood disorders (MDs); anxiety disorders (ADs); alcohol use disorders (AUDs); substance use disorders (SUDs); and psychotic disorders (PDs). Using multivariable logistic regression models, we explored the factors associated with NUMT among the MINI-positive respondents. The odds ratio and 95% confidence interval were calculated for each factor.

Results

In total, 12,818 (32.4%) respondents were MINI-positive, 46.5% of them reported NUMT (35.6% for MDs, 39.7% for PDs, 42.8% for ADs, 56.0% for AUDs, and 56.7% for SUDs). NUMT was positively associated with being male [OR 1.75 (1.59–1.91)] and practising religion [OR 1.13 (1.02–1.25)] and negatively associated with ageing [per 10-year increase: OR 0.88 (0.85–0.91)], being single [OR 0.74 (0.66–0.84)], being a French native [OR 0.67 (0.60–0.75)], and experiencing MDs [OR 0.39 (0.36–0.43)], ADs [OR 0.47 (0.43–0.52)], AUDs [OR 0.83 (0.73–0.96)], SUDs [OR 0.77 (0.65–0.91)], or PDs [OR 0.50 (0.43–0.59)].

Conclusions

In France, NUMT rates were the highest for AUDs and SUDs. Additionally, suffering from MDs or ADs increased the lifetime treatment utilization for people having any other mental disorder. This finding emphasizes the need to better screen AUDs and SUDs among people treated for MDs or ADs.

Keywords

Mental health Treatment utilization Epidemiology France 

Notes

Acknowledgements

The MHGP survey was funded by the French Ministry for Health. The work undertaken in this study was funded by a Grant from the Fondation Actions-Addictions (https://www.actions-addictions.org), which is an independent non-profit foundation promoting evidence-based action against addiction in France.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Kohn R, Saxena S, Levav I, Saraceno B (2004) The treatment gap in mental health care. Bull World Health Org 82:858–866 /S0042-96862004001100011PubMedPubMedCentralGoogle Scholar
  2. 2.
    Knapp M, McDaid D, Mossialos E, Thornicroft G (2014) Mental health policy and practice across Europe. The future direction of mental health care. World Health Organization, GenevaGoogle Scholar
  3. 3.
    Sipe TA, Finnie RKC, Knopf JA et al (2015) Effects of mental health benefits legislation: a community guide systematic review. Am J Prev Med 48:755–766.  https://doi.org/10.1016/j.amepre.2015.01.022 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Burnett-Zeigler I, Zivin K, Islam K, Ilgen MA (2012) Longitudinal predictors of first time depression treatment utilization among adults with depressive disorders. Soc Psychiatry Psychiatr Epidemiol 47:1617–1625.  https://doi.org/10.1007/s00127-011-0465-6 CrossRefPubMedGoogle Scholar
  5. 5.
    Ilgen MA, Price AM, Burnett-Zeigler I et al (2011) Longitudinal predictors of addictions treatment utilization in treatment-naïve adults with alcohol use disorders. Drug Alcohol Depend 113:215–221.  https://doi.org/10.1016/j.drugalcdep.2010.08.006 CrossRefPubMedGoogle Scholar
  6. 6.
    Fink DS, Sampson L, Tamburrino MB et al (2015) Lifetime and 12-month use of psychiatric services among US Army National Guard soldiers in Ohio. Psychiatr Serv Wash DC 66:514–520.  https://doi.org/10.1176/appi.ps.201400128 CrossRefGoogle Scholar
  7. 7.
    Cohen E, Feinn R, Arias A, Kranzler HR (2007) Alcohol treatment utilization: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 86:214–221.  https://doi.org/10.1016/j.drugalcdep.2006.06.008 CrossRefPubMedGoogle Scholar
  8. 8.
    Grolleau A, Cougnard A, Bégaud B, Verdoux H (2008) Congruence between diagnosis of recurrent major depressive disorder and psychotropic treatment in the general population. Acta Psychiatr Scand 117:20–27.  https://doi.org/10.1111/j.1600-0447.2007.01109.x PubMedGoogle Scholar
  9. 9.
    Bellamy V, Roelandt J-L, Caria A (2004) Troubles mentaux et représentations de la santé mentale: premiers résultats de l’enquête Santé Mentale en Population Générale. DREES 347:1–12Google Scholar
  10. 10.
    Amad A, Guardia D, Salleron J et al (2013) Increased prevalence of psychotic disorders among third-generation migrants: results from the French Mental Health in General Population survey. Schizophr Res 147:193–195.  https://doi.org/10.1016/j.schres.2013.03.011 CrossRefPubMedGoogle Scholar
  11. 11.
    Pignon B, Pierre Alexis G, Thomas P et al (2017) Prevalence and clinical severity of mood disorders among first-, second- and third-generation migrants. J Affect Disord 210:174–180.  https://doi.org/10.1016/j.jad.2016.12.039 CrossRefPubMedGoogle Scholar
  12. 12.
    Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 2):22–33 (quiz 34–57) PubMedGoogle Scholar
  13. 13.
    Howard KI, Cornille TA, Lyons JS et al (1996) Patterns of mental health service utilization. Arch Gen Psychiatry 53:696–703CrossRefPubMedGoogle Scholar
  14. 14.
    Jokela M, Batty GD, Vahtera J et al (2013) Socioeconomic inequalities in common mental disorders and psychotherapy treatment in the UK between 1991 and 2009. Br J Psychiatry 202:115–120.  https://doi.org/10.1192/bjp.bp.111.098863 CrossRefPubMedGoogle Scholar
  15. 15.
    Jokela M, Batty GD, Kivimäki M (2013) Ageing and the prevalence and treatment of mental health problems. Psychol Med 43:2037–2045.  https://doi.org/10.1017/S0033291712003042 CrossRefPubMedGoogle Scholar
  16. 16.
    Alegría M, Bijl RV, Lin E et al (2000) Income differences in persons seeking outpatient treatment for mental disorders: a comparison of the United States with Ontario and The Netherlands. Arch Gen Psychiatry 57:383–391CrossRefPubMedGoogle Scholar
  17. 17.
    Wu L-T, Zhu H, Mannelli P, Swartz MS (2017) Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. Drug Alcohol Depend 177:153–162.  https://doi.org/10.1016/j.drugalcdep.2017.03.037 CrossRefPubMedGoogle Scholar
  18. 18.
    Compton WM, Thomas YF, Stinson FS, Grant BF (2007) Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 64:566–576.  https://doi.org/10.1001/archpsyc.64.5.566 CrossRefPubMedGoogle Scholar
  19. 19.
    Wu L-T, Ringwalt CL, Williams CE (2003) Use of substance abuse treatment services by persons with mental health and substance use problems. Psychiatr Serv Wash DC 54:363–369.  https://doi.org/10.1176/appi.ps.54.3.363 CrossRefGoogle Scholar
  20. 20.
    Mackenzie CS, Reynolds K, Cairney J et al (2012) Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidity. Depress Anxiety 29:234–242.  https://doi.org/10.1002/da.20911 CrossRefPubMedGoogle Scholar
  21. 21.
    Iza M, Olfson M, Vermes D et al (2013) Probability and predictors of first treatment contact for anxiety disorders in the United States. J Clin Psychiatry 74:1093–1100.  https://doi.org/10.4088/JCP.13m08361 CrossRefPubMedGoogle Scholar
  22. 22.
    Olfson M, Liu S-M, Grant BF, Blanco C (2012) Influence of comorbid mental disorders on time to seeking treatment for major depressive disorder. Med Care 50:227–232.  https://doi.org/10.1097/MLR.0b013e318241eb5e CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    De Witte NAJ, Crunelle CL, Sabbe B et al (2014) Treatment for outpatients with comorbid schizophrenia and substance use disorders: a review. Eur Addict Res 20:105–114.  https://doi.org/10.1159/000355267 CrossRefPubMedGoogle Scholar
  24. 24.
    Henriksen CA, Stein MB, Afifi TO et al (2015) Identifying factors that predict longitudinal outcomes of untreated common mental disorders. Psychiatr Serv 66:163–170.  https://doi.org/10.1176/appi.ps.201300564 CrossRefPubMedGoogle Scholar
  25. 25.
    Davis LL, Wisniewski SR, Howland RH et al (2010) Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STARD level one treatment outcomes. Drug Alcohol Depend 107:161–170.  https://doi.org/10.1016/j.drugalcdep.2009.10.003 CrossRefPubMedGoogle Scholar
  26. 26.
    Howland RH, John Rush A, Wisniewski SR et al (2009) Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend 99:248–260.  https://doi.org/10.1016/j.drugalcdep.2008.08.010 CrossRefPubMedGoogle Scholar
  27. 27.
    Sareen J, Henriksen CA, Stein MB et al (2013) Common mental disorder diagnosis and need for treatment are not the same: findings from a population-based longitudinal survey. Psychol Med 43:1941–1951.  https://doi.org/10.1017/S003329171200284X CrossRefPubMedGoogle Scholar
  28. 28.
    Tuithof M, ten Have M, van den Brink W et al (2016) Treatment seeking for alcohol use disorders: treatment gap or adequate self-selection? Eur Addict Res 22:277–285.  https://doi.org/10.1159/000446822 CrossRefPubMedGoogle Scholar
  29. 29.
    Rodriguez-Seijas C, Eaton NR, Stohl M et al (2017) Mental disorder comorbidity and treatment utilization. Compr Psychiatry.  https://doi.org/10.1016/j.comppsych.2017.02.003 PubMedGoogle Scholar
  30. 30.
    Lasalvia A, Zoppei S, Van Bortel T et al (2013) Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey. Lancet Lond Engl 381:55–62.  https://doi.org/10.1016/S0140-6736(12)61379-8 CrossRefGoogle Scholar
  31. 31.
    Sartorius N (2007) Stigma and mental health. Lancet 370:810–811.  https://doi.org/10.1016/S0140-6736(07)61245-8 CrossRefPubMedGoogle Scholar
  32. 32.
    Hasin DS, Grant BF (2015) The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol 50:1609–1640.  https://doi.org/10.1007/s00127-015-1088-0 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Choi NG, DiNitto DM, Marti CN (2014) Treatment use, perceived need, and barriers to seeking treatment for substance abuse and mental health problems among older adults compared to younger adults. Drug Alcohol Depend 145:113–120.  https://doi.org/10.1016/j.drugalcdep.2014.10.004 CrossRefPubMedGoogle Scholar
  34. 34.
    Nobles CJ, Valentine SE, Gerber MW et al (2016) Predictors of treatment utilization and unmet treatment need among individuals with posttraumatic stress disorder from a national sample. Gen Hosp Psychiatry 43:38–45.  https://doi.org/10.1016/j.genhosppsych.2016.09.001 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gum AM, Iser L, King-Kallimanis BL et al (2011) Six-month longitudinal patterns of mental health treatment utilization by older adults with depressive symptoms. Psychiatr Serv 62:1353–1360.  https://doi.org/10.1176/ps.62.11.pss6211_1353 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bellido-Zanin G, Ángeles Pérez-San-Gregorio M, Martín-Rodríguez A, Vázquez-Morejón AJ (2015) Social functioning as a predictor of the use of mental health resources in patients with severe mental disorder. Psychiatry Res 230:189–193.  https://doi.org/10.1016/j.psychres.2015.08.037 CrossRefPubMedGoogle Scholar
  37. 37.
    Mann CJ (2003) Observational research methods. Research design II: cohort, cross sectional, and case–control studies. Emerg Med J 20:54–60.  https://doi.org/10.1136/emj.20.1.54 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kovess-Masfety V, Alonso J, Brugha TS et al (2007) Differences in lifetime use of services for mental health problems in six European countries. Psychiatr Serv 58:213–220.  https://doi.org/10.1176/ps.2007.58.2.213 CrossRefPubMedGoogle Scholar
  39. 39.
    Salize HJ, Werner A, Jacke CO (2013) Service provision for mentally disordered homeless people. Curr Opin Psychiatry 26:355–361.  https://doi.org/10.1097/YCO.0b013e328361e596 CrossRefPubMedGoogle Scholar
  40. 40.
    Rolland B, Geoffroy P-A, Pignon B et al (2017) Alcohol use disorders and immigration up to the third generation in france: findings from a 39,617-subject survey in the general population. Alcohol Clin Exp Res.  https://doi.org/10.1111/acer.13387 PubMedGoogle Scholar
  41. 41.
    Susser E, Conover S, Struening EL (1989) Problems of epidemiologic method in assessing the type and extent of mental illness among homeless adults. Hosp Community Psychiatry 40:261–265PubMedGoogle Scholar
  42. 42.
    Szerman N, Vega P, Grau-López L et al (2014) Dual diagnosis resource needs in Spain: a national survey of professionals. J Dual Diagn 10:84–90.  https://doi.org/10.1080/15504263.2014.906195 CrossRefPubMedGoogle Scholar
  43. 43.
    Balhara YPS, Lev-Ran S, Martínez-Raga J et al (2016) State of training, clinical services, and research on dual disorders across France, India, Israel, and Spain. J Dual Diagn 12:252–260.  https://doi.org/10.1080/15504263.2016.1254309 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Hélène Font
    • 1
  • Jean-Luc Roelandt
    • 1
  • Hélène Behal
    • 2
  • Pierre-Alexis Geoffroy
    • 3
    • 4
  • Baptiste Pignon
    • 5
    • 6
    • 7
    • 8
  • Ali Amad
    • 9
    • 11
  • Nicolas Simioni
    • 12
  • Guillaume Vaiva
    • 9
    • 11
  • Pierre Thomas
    • 9
    • 11
  • Alain Duhamel
    • 2
  • Imane Benradia
    • 1
  • Benjamin Rolland
    • 9
    • 10
    • 13
    • 14
  1. 1.Centre Collaborateur de l’Organisation Mondiale de la SantéHellemmesFrance
  2. 2.Département de BiostatistiquesUniv. Lille, CHU Lille, EA 2694, Santé publique: épidémiologie et qualité des soinsLilleFrance
  3. 3.AP-HP, GH Saint-Louis, Lariboisière, Fernand Widal, Pôle NeurosciencesParisFrance
  4. 4.Université Paris Diderot, UMR-S 1144ParisFrance
  5. 5.AP-HP, DHU PePSY, Hôpitaux Universitaires Henri Mondor, Pôle Psychiatrie AddictologieCréteilFrance
  6. 6.INSERM, U955, équipe 15CréteilFrance
  7. 7.Fondation FondaMentalCréteilFrance
  8. 8.UPEC, Université Paris-Est, Faculté de médecineCréteilFrance
  9. 9.Pôle de Psychiatrie et Addictologie, CHRU de LilleLilleFrance
  10. 10.INSERM U1171, Univ LilleLilleFrance
  11. 11.UMR9193-PsychiC-SCALab, Department of PsychiatryUniv. Lille, CNRS, CHU de LilleLilleFrance
  12. 12.Fondation Phénix, Centre Phénix PlainpalaisGenevaSwitzerland
  13. 13.Service Universitaire d’Addictologie de Lyon (SUAL), CH Le VinatierBronFrance
  14. 14.Université de Lyon, UCBLLyonFrance

Personalised recommendations